Compare QTRX & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | STXS |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 190.6M |
| IPO Year | 2017 | 2004 |
| Metric | QTRX | STXS |
|---|---|---|
| Price | $2.61 | $2.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.4M | 325.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | $29,346,617.00 |
| Revenue This Year | $25.49 | $28.22 |
| Revenue Next Year | $10.04 | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $1.70 |
| 52 Week High | $8.77 | $3.59 |
| Indicator | QTRX | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 35.48 | 58.32 |
| Support Level | $2.40 | $1.97 |
| Resistance Level | $3.74 | $2.12 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 23.76 | 82.43 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.